LAUNCHING THE
FIRST
TOKENIZED
AGING TRIAL

PROBLEM

Aging kills, solutions locked

- Aging drives diseases and death
- The FDA doesn’t recognize aging
- $1B+, 10+ years for approval
- Sliver tsunami incoming

“...has blood on its hands”

Wild west gray market

- Stem cell therapy gray market $18B
- 100K+ treated annually
- **Fragmented, unverifiable, no standards, mostly fraudulent**

PERFECT STORM

DeSci as the next frontier of crypto

Regulatory revolution, startup cities, expanded right-to-try

ns.com

INFINITA CITY

Stem cells show incredible promise for life extension









ANTI AGING THERAPY

Research Lab

TURGEMAN LAB

ARIEL UNIVERSITY

Stem cells

Neuroregeneration

Bioproduction Partner

NurExone biologic

Qualified labs in Haifa

High yield cell line

Anti-inflammatory cell secretome derived from Mesenchymal Stem Cells, administered intranasally

Targets biological aging

Excellent safety profile

Our Data

Reverses senescence

Improves memory

Neurogenesis (shown)



CLINICAL TRIAL

Aging Endpoint

LinAge2

Measure aging, not diseases
Based on blood markers
Clinically validated

Lead Researcher

Prof. Brian Kennedy,
Director, Centre for Healthy Longevity, NUS

Trial Site

Data Moat

Real data, not anecdotes
Transparency = Credibility

Decentralized Medical Committee

From multiple jurisdictions

TOKENIZATION

- Tokens align incentives for patients, clinics, and contributors
- Virality unlocks scalable funding
- Token-gated priority access to treatments
- Seamless shared ownership and coordination



MARKET

Anti Aging Medicine

- Positioned for cash-pay longevity clinics and wellness networks
- Builds data onramp for expansion into chronic conditions

Age Related Diseases

- Disease modifying potential for e.g. Alzheimer’s, cardiovascular
- Huge unmet need, no effective treatments

Annual sales

kimera EXOSOMES

$75M (23')

ExoCoBio

$24M (22')

DIRECT BIOLOGICS

$18M (21')

BUSINESS MODEL

Day8 Program = 8 days program

1 administration every day for 8 days, recurrent
Cost: $8,000 USDC

Sales to Premium Clinics

Year 1: 10 Clinics x 100 treatments per year X $8K = $8,000,000 revenue

IP Sublicensing to Strategic Partners

Leverage clinical-grade data to sublicense to larger pharma or wellness companies

Token Trading Fees

For continual replenishment of the treasury

Leverage Medical Innovation Jurisdictions Worldwide

Established ties in Malaysia, Thailand, Prospera, Oman, Germany

TEAM



Asher Raziel, Co-founder, CEO

Biotech operator, crypto native. American-Israeli. Raised VC funding for gene therapy biomanufacturing startup and personal bioreactor startup. Setup Phase 1 gene therapy trial in Prospera in 2021. BIO Protocol contributor. Duke uni BSc.

Tomer Landsberger, Co-founder, CSO

Israeli comp bio, PhD Immunology Weizmann Institute, Physics MSc, Philosophy MA. Ex Gero, VitaDAO dealflow, LBF Tel Aviv director, Michael Levin's lab. Founded Sciborg. Deeply integrated into the longevity ecosystem. Spent the last two years living in pop-up cities around the world. Transhumanist.



Shay Geula, Head of R&D

Stem Cell & Aging Scientist. PhD Weizmann Institute, post-doc University of Texas. Co-founder of CatchMe Therapeutics & Renewal Bio, pioneering RNA-based therapeutics and innovative cell therapy solutions.

Gadi Turgeman, CAB

PI at Ariel University with 20 years' cell-biology experience; investigates mesenchymal stem cells, extracellular vesicles, and adult neurogenesis to develop therapies for neurobehavioral disorders and brain aging, including a current US-Israel BSF project on EVs for brain aging.

TRACTION

- Recruited KOL Brian Kennedy from National University of Singapore to sponsor trial
- 2 year research program developing flagship anti aging product at Ariel University
- Negotiating partnership with NurExone for product production
- Onboarded with BIO.xyz for token launch

NUS National University of Singapore

ARIEL UNIVERSITY

NurExone biologic

BIO

ROADMAP


Strategic deals: NUS, Ariel, NurExone
Clinics LOIs
GMP lot released
Recruit patients
Q3 25
Q4 25
Q1 26
Q2 26
Treatment enters clinics
Finalize trial design
Tokenomics v1 + legal opinion
IRB approval
Launch $DAY8 token